Galmed Pharmaceuticals
GLMD
18 hedge funds and large institutions have $14.8M invested in Galmed Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0% more funds holding
Funds holding: 18 → 18 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
41% less capital invested
Capital invested by funds: $25M → $14.8M (-$10.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$583K |
| 2 |
Renaissance Technologies
New York
|
+$420K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$361K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$315K |
| 5 |
Morgan Stanley
New York
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.16M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$746K |
| 3 |
JGC
J. Goldman & Co
New York
|
-$291K |
| 4 |
CA
CapWealth Advisors
Franklin,
Tennessee
|
-$109K |
| 5 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$46.6K |
GLMD Hedge Fund Activity: Q1 2018 in Review
18 of the 4,372 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2018, worth a combined $14.8M — down 41% from $25M a quarter earlier.
Fund positioning in GLMD was balanced in Q1 2018: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 3 trimmed.
The largest buyer was Park West Asset Management, adding an estimated $583K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.16M sold.
- 18 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $14.8M of Galmed Pharmaceuticals stock for Q1 2018, down 41% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q1 2018 and 3 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2018 was Park West Asset Management, an estimated $583K added.
- The largest Galmed Pharmaceuticals seller in Q1 2018 was Sphera Funds Management, an estimated $2.16M sold.
Based on aggregated 13F filings for Q1 2018.